| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/14/2004 | EP1406879A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406877A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 04/14/2004 | EP1406876A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 04/14/2004 | EP1406872A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406871A2 Process for the production of n- 3-(3-cyanopyrazolo 1,5-a] pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) |
| 04/14/2004 | EP1406870A1 Taxol enhancer compounds |
| 04/14/2004 | EP1406869A1 Taxol enhancer compounds |
| 04/14/2004 | EP1406867A2 Thiolalkyl benzoic acid derivatives |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406862A1 Substituted aminoalcohols useful in treatment of alzheimer's disease |
| 04/14/2004 | EP1406859A1 Substituted 4-aminocyclohexanol derivatives |
| 04/14/2004 | EP1406858A1 Substituted 4-aminocyclohexanols |
| 04/14/2004 | EP1406854A1 Process and intermediates to prepare latanoprost |
| 04/14/2004 | EP1406700A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 04/14/2004 | EP1406699A1 Antitumoral formulations of thioxanthenone |
| 04/14/2004 | EP1406698A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 04/14/2004 | EP1406697A2 Use of magnesium for preventing in-stent thrombosis and complications after arterial angioplasty with stent placement |
| 04/14/2004 | EP1406696A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 04/14/2004 | EP1406694A1 Electro-medical device for use with biologics |
| 04/14/2004 | EP1406682A1 Drug delivery devices |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406662A1 Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| 04/14/2004 | EP1406661A1 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406658A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406654A2 Methods for regulating bacteria |
| 04/14/2004 | EP1406647A1 Use of antimicrobial peptides as preservatives in ophthalmic preparations including solutions emulsions and suspensions |
| 04/14/2004 | EP1406643A2 Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ |
| 04/14/2004 | EP1406641A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 04/14/2004 | EP1406640A2 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy |
| 04/14/2004 | EP1406639A2 Method for enhancing the effectiveness of cancer therapies |
| 04/14/2004 | EP1406638A2 Macrophage receptor agonist or antagonist |
| 04/14/2004 | EP1406637A2 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 04/14/2004 | EP1406635A2 A controlled release anti-inflammatory formulation and a process for the preparation thereof |
| 04/14/2004 | EP1406634A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 04/14/2004 | EP1406633A1 Enhanced drug delivery in transdermal systems |
| 04/14/2004 | EP1406632A2 Substituted 3-aryl-5-aryl- 1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 04/14/2004 | EP1406631A2 Dopamine receptor ligands and therapeutic methods based thereon |
| 04/14/2004 | EP1406630A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 04/14/2004 | EP1406629A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 04/14/2004 | EP1406628A1 Tetrahydroquinoline derivatives |
| 04/14/2004 | EP1406627A1 Pyridin-2-yl-methlyamine derivatives for treating opioid dependence |
| 04/14/2004 | EP1406626A2 Sulphonyl aryl hydroxamates and their use as mmp inhibitors |
| 04/14/2004 | EP1406625A1 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS |
| 04/14/2004 | EP1406622A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406621A2 Compositions and methods for inhibiting platelet activation and thrombosis |
| 04/14/2004 | EP1406620A1 Vinyl phenyl derivatives as glk activators |
| 04/14/2004 | EP1406618A2 Use of nk-1 receptor antagonists with pyridinic structure for the treatment of brain, spinal or nerve injury |
| 04/14/2004 | EP1406617A1 Diaminediols for the treatment of alzheimer's disease |
| 04/14/2004 | EP1406616A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/14/2004 | EP1406615A1 Kinase inhibitors and the use thereof |
| 04/14/2004 | EP1406614A2 Carvedilol polymorph |
| 04/14/2004 | EP1406613A1 Organic nitrate-based compounds for the treatment of vasculopathies |
| 04/14/2004 | EP1406612A1 Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic dystamycin a for the treatment of beta-thalassaemia |
| 04/14/2004 | EP1406611A2 Method for treating fibrotic diseases or other indications |
| 04/14/2004 | EP1406610A1 Use of substituted gamma-lactone compounds as medicaments |
| 04/14/2004 | EP1406609A2 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/14/2004 | EP1406608A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| 04/14/2004 | EP1406607A2 Verwendung einer antiviralen verbindungsklasse (dithiocarbamat-verbindungen) zur herstellung eines mittels zur behandlung bzw. pravention einer virusinfektion im respiratorischen trakt |
| 04/14/2004 | EP1406606A1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/14/2004 | EP1406605A1 Carbamates of 2-heterocyclic-1,2-ethanediols |
| 04/14/2004 | EP1406604A2 Topical application of muscarinic analgesic drugs such as neostigmine |
| 04/14/2004 | EP1406603A2 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 04/14/2004 | EP1406602A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 04/14/2004 | EP1406601A2 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
| 04/14/2004 | EP1406600A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 04/14/2004 | EP1406599A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 04/14/2004 | EP1406598A1 Lymphatic drug delivery system |
| 04/14/2004 | EP1406597A1 Controlled drug delivery systems providing variable release rates |
| 04/14/2004 | EP1406591A1 Pharmaceutical composition for nasal delivery of estradiol and norethisterone |
| 04/14/2004 | EP1406586A2 Cosmetic and dermatological preparations containing carnitine, for treating and actively preventing dry skin and other negative alterations in the physiological homeostasis of healthy skin |
| 04/14/2004 | EP1406578A1 Cationic antibacterial dentifrice exhibiting superior foaming properties |
| 04/14/2004 | EP1406572A2 Pediatric formulation of gatifloxacin |
| 04/14/2004 | EP1406571A2 Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| 04/14/2004 | EP1406568A1 Sequential drug delivery systems |
| 04/14/2004 | EP1406516A1 Potassium calcium citrate compositions and methods for their production |
| 04/14/2004 | EP1406514A1 Enteral formulations |
| 04/14/2004 | EP1406496A1 Method and composition for enhancing sexual desire |
| 04/14/2004 | EP1406495A1 Method for reducing muscle fatigue through administration of adenosine triphosphate |
| 04/14/2004 | EP1406489A2 Eukaryotic genes involved in adult lifespan regulation |
| 04/14/2004 | EP1380295A9 Photosensitiser and method for production thereof |
| 04/14/2004 | EP1375465A9 Cyclooctanone derivative and cyclodecanone derivative, and use thereof |
| 04/14/2004 | EP1301522A4 Novel compounds and methods |
| 04/14/2004 | EP1286954B1 7-substituted fused ring tetracycline compounds |
| 04/14/2004 | EP1274426B1 Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis |
| 04/14/2004 | EP1230252B1 Beta-d-5-thioxylose derivatives, preparation method and therapeutic use |
| 04/14/2004 | EP1218063B1 Pharmaceutical composition containing trichloroacetic acid, 2-oh benzoic acid and menthol for topical application and process for the preparation thereof |
| 04/14/2004 | EP1214312B1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 04/14/2004 | EP1214299B1 Muscarinic antagonists |
| 04/14/2004 | EP1213296B1 Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 04/14/2004 | EP1202994B1 New compounds |
| 04/14/2004 | EP1200419B1 Aminothiazole derivatives and their use as crf receptor ligands |
| 04/14/2004 | EP1189583A4 Indole derivatives |
| 04/14/2004 | EP1171440B1 Substituted-3-cyano-[1.7],[1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases |
| 04/14/2004 | EP1140072B1 Compounds and methods |